KIT and neoplasm: Ultimately, though, routine performance in the clinical laboratory of MC-specific genome sequencing (using pipelines already in place in many laboratories for sequencing the tumor cells in biopsies, but re-tuned, likely based on strong CD117 expression, to select the MCs in the sample) will be needed to discover not only which mutational profiles reliably correlate with which symptom profiles but also which treatments will best address the phenotypes driven by particular mutational profiles.